The Cancer Patent Cliff: Why Watchful Waiting May Be The Best Rx For High Drug Costs
As efforts are made to try new reimbursement and pricing models to address concerns about the price of cancer drugs, one option is to wait and see if generics and biosimilars solve the problem.
You may also be interested in...
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.
Recent cases of individual designed treatments have FDA playing a bit of catch up. The concept has been on the horizon, but now “bespoke therapies” are here.